Abacavir hydroxyacetate | Prurisol | CAS#1446418-48-9 | plaque psoriasis

MedKoo Cat#: 529107 | Name: Abacavir hydroxyacetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Prurisol, also known as abacavir hydroxyacetate and KM-133, is potentially for the treatment of plaque psoriasis

Chemical Structure

Abacavir hydroxyacetate

CAS#1446418-48-9 (hydroxyacetate)

Theoretical Analysis

MedKoo Cat#: 529107

Name: Abacavir hydroxyacetate

CAS#: 1446418-48-9 (hydroxyacetate)

Chemical Formula: C16H20N6O3

Exact Mass: 344.1597

Molecular Weight: 344.37

Elemental Analysis: C, 55.80; H, 5.85; N, 24.40; O, 13.94

Price and Availability

Size	Price	Availability
1mg	USD 90.00	Ready to ship
5mg	USD 150.00	Ready to ship
10mg	USD 250.00	Ready to ship
25mg	USD 550.00	Ready to ship
50mg	USD 950.00	Ready to ship
100mg	USD 1,650.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

136470-78-5 (free base) 136777-48-5 (HCl) 168146-84-7 (succinate) 188062-50-2 (sulfate) 1446418-48-9 (hydroxyacetate) 384380-52-3 (carboxylate)

Synonym

KM-133; KM133; KM 133; Prurisol; Abacavir acetate; Abacavir hydroxyacetate;

IUPAC/Chemical Name

((1S,4R)-4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)cyclopent-2-en-1-yl)methyl 2-hydroxyacetate

InChi Key

ZBBZROWQLKCFQK-KOLCDFICSA-N

InChi Code

InChI=1S/C16H20N6O3/c17-16-20-14(19-10-2-3-10)13-15(21-16)22(8-18-13)11-4-1-9(5-11)7-25-12(24)6-23/h1,4,8-11,23H,2-3,5-7H2,(H3,17,19,20,21)/t9-,11+/m1/s1

SMILES Code

O=C(OC[C@@H]1C=C[C@H](N2C=NC3=C(NC4CC4)N=C(N)N=C23)C1)CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot# T21D12P04

QC Data

View QC data: current batch, Lot# T21D12P04

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

KM-133 is potential treatment for plaque psoriasis.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	0.0	0.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 344.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Fantauzzi A, Floridia M, Falasca F, Spanedda P, Turriziani O, Vullo V, Mezzaroma I. Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. New Microbiol. 2015 Oct 20;38(4). [Epub ahead of print] PubMed PMID: 26485011. 2: Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2015 Oct 5. pii: S1473-3099(15)00319-9. doi: 10.1016/S1473-3099(15)00319-9. [Epub ahead of print] PubMed PMID: 26481928. 3: Naisbitt DJ, Yang EL, Alhaidari M, Berry NG, Lawrenson AS, Farrell J, Martin P, Strebel K, Owen A, Pye M, French N, Clarke SE, O'Neill PM, Park BK. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS. 2015 Sep 13. [Epub ahead of print] PubMed PMID: 26372480. 4: Wilson B, Paladugu L, Priyadarshini SR, Jenita JJ. Development of albumin-based nanoparticles for the delivery of abacavir. Int J Biol Macromol. 2015 Sep 10;81:763-767. doi: 10.1016/j.ijbiomac.2015.09.015. [Epub ahead of print] PubMed PMID: 26365020. 5: Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015 Sep 9. [Epub ahead of print] PubMed PMID: 26355674. 6: Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Aug 7. [Epub ahead of print] PubMed PMID: 26262777. 7: Gao S, Zhu S, Huang R, Lu Y, Zheng G. Efficient synthesis of the intermediate of abacavir and carbovir using a novel (+)-γ-lactamase as a catalyst. Bioorg Med Chem Lett. 2015 Sep 15;25(18):3878-81. doi: 10.1016/j.bmcl.2015.07.054. Epub 2015 Jul 26. PubMed PMID: 26235952. 8: Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med. 2015 Jul 14. doi: 10.1111/hiv.12281. [Epub ahead of print] PubMed PMID: 26176344. 9: Neumanova Z, Cerveny L, Greenwood SL, Ceckova M, Staud F. Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reprod Toxicol. 2015 Nov;57:176-82. doi: 10.1016/j.reprotox.2015.07.070. Epub 2015 Jul 10. PubMed PMID: 26169552. 10: Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. PubMed PMID: 26133089.